The identification and characterization of gene signatures, driver events, and pharmacogenomics in molecularly homogeneous subsets of patients is likely to advance effective drug development strategies in colorectal cancer.
Ramon Salazar, MD, PhD
Advertisement
Articles by Ramon Salazar, MD, PhD
Advertisement
Latest Updated Articles
- Genomic Testing in Colorectal Cancer: How Much Is Enough?
Published: March 15th 2015 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Frontline Alectinib Upholds OS Benefit in Advanced ALK+ NSCLC
2
Sevabertinib Monotherapy Elicits Durable Responses in HER2-Mutant NSCLC
3
Zongertinib Maintains Efficacy Benefit in First-line HER2-Mutated NSCLC
4
Episode 16: Anticipated ESMO 2025 Data That May Change GU Oncology
5
